Non-IgG antibodies are gaining increasing attention in therapeutic discovery and biotechnological research because they offer structural flexibility, compact molecular size, modular design potential, and unique biological advantages that conventional IgG antibodies mayRead More…
For decades, the therapeutic antibody landscape has been heavily dominated by the Immunoglobulin G (IgG) isotype. Its long serum half-life, well-understood pharmacokinetics, and manageable structural properties have made it the gold standardRead More…
The landscape of therapeutic antibodies is rapidly evolving. For decades, the biopharmaceutical industry has heavily relied on the standard Immunoglobulin G (IgG) framework to develop life-saving treatments for oncology, autoimmune diseases, andRead More…
For decades, the biopharmaceutical landscape has been dominated by Immunoglobulin G (IgG). Its favorable half-life, well-understood structure, and established manufacturing processes have made it the gold standard for monoclonal antibody (mAb) therapeutics. However,Read More…
Non-IgG antibodies—especially IgA, IgM, and IgE—are re-entering biologics pipelines for reasons IgG cannot always match: mucosal targeting, high avidity through multivalency, and specialized effector biology. But the same structural features that makeRead More…
IgG has been the “default chassis” for therapeutic antibodies for decades—and for good reason: mature discovery workflows, predictable developability, well-characterized Fc effector biology, and scalable manufacturing. But the industry’s IgG-centric comfort zoneRead More…
Antimicrobial resistance (AMR) is steadily eroding the impact of conventional antibiotics. Every year, hundreds of thousands of deaths are already attributed to drug-resistant infections, and projections indicate that, without new strategies, thisRead More…
Allergic diseases share a common inflammatory logic: epithelial “danger” signals activate a type-2 cascade that culminates in IgE-armed effector cells and rapid symptom flares on re-exposure. Monoclonal antibodies (mAbs) that intercept thisRead More…
Immunoglobulin M (IgM) is a crucial component of the primary immune response. As the first line of defense, these antibodies are known for their high avidity—the collective strength of multiple antibody-antigen bindingRead More…
Immunoglobulin M (IgM) is the most ancient and structurally distinctive immunoglobulin isotype in the vertebrate immune system. Though often overshadowed by IgG and IgA, IgM plays a critical role in shaping earlyRead More…